MA40858A - Composés antagonistes des récepteurs d3 à la dopamine - Google Patents
Composés antagonistes des récepteurs d3 à la dopamineInfo
- Publication number
- MA40858A MA40858A MA040858A MA40858A MA40858A MA 40858 A MA40858 A MA 40858A MA 040858 A MA040858 A MA 040858A MA 40858 A MA40858 A MA 40858A MA 40858 A MA40858 A MA 40858A
- Authority
- MA
- Morocco
- Prior art keywords
- dopamine
- receptor antagonist
- antagonist compounds
- compounds
- receptor
- Prior art date
Links
- 229940088353 Dopamine D3 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000002300 dopamine 3 receptor blocking agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1419430.2A GB201419430D0 (en) | 2014-10-31 | 2014-10-31 | Dopamine D3 receptor antagonist compounds |
| GBGB1419433.6A GB201419433D0 (en) | 2014-10-31 | 2014-10-31 | Dopamine D3 receptor antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40858A true MA40858A (fr) | 2021-03-31 |
Family
ID=54427799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040858A MA40858A (fr) | 2014-10-31 | 2015-10-30 | Composés antagonistes des récepteurs d3 à la dopamine |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10000477B2 (enExample) |
| EP (1) | EP3212637B1 (enExample) |
| JP (1) | JP2017532364A (enExample) |
| KR (1) | KR20170090422A (enExample) |
| CN (1) | CN107108597B (enExample) |
| AU (1) | AU2015340308B2 (enExample) |
| CA (1) | CA2964103C (enExample) |
| DK (1) | DK3212637T3 (enExample) |
| ES (1) | ES2883831T3 (enExample) |
| IL (2) | IL251725B (enExample) |
| MA (1) | MA40858A (enExample) |
| MX (1) | MX2017005484A (enExample) |
| NZ (1) | NZ731118A (enExample) |
| RU (1) | RU2017118562A (enExample) |
| SG (1) | SG11201702982UA (enExample) |
| WO (1) | WO2016067043A1 (enExample) |
| ZA (1) | ZA201702765B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017532364A (ja) * | 2014-10-31 | 2017-11-02 | インディビオール・ユー・ケイ・リミテッド | ドーパミンｄ３レセプターのアンタゴニスト化合物 |
| CN106883192B (zh) * | 2017-03-30 | 2019-05-14 | 苏州汉德创宏生化科技有限公司 | 含氮类杂环抗肿瘤药物活性物恶唑基修饰的苯甲酸类化合物的合成方法 |
| WO2019146740A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CA3150108A1 (en) * | 2019-09-13 | 2021-03-18 | Neelu Kaila | Hpk1 antagonists and uses thereof |
| PE20221453A1 (es) | 2019-10-09 | 2022-09-21 | Novartis Ag | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
| CN119390705A (zh) | 2019-10-09 | 2025-02-07 | 诺华股份有限公司 | 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物 |
| CN110981795B (zh) * | 2019-12-18 | 2021-02-12 | 武汉世纪久海检测技术有限公司 | 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法 |
| TW202136253A (zh) * | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Ｔｒｐｍｌ調節劑 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN116120213B (zh) * | 2021-06-11 | 2024-09-13 | 重庆医药高等专科学校 | 反式4-(叔丁氧羰氨基)环己烷羧酸的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654305A (en) * | 1970-01-26 | 1972-04-04 | Robins Co Inc A H | 5-azaspiro(2.4)heptanes |
| WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| WO1993000313A2 (en) | 1991-06-27 | 1993-01-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| JP2003516967A (ja) | 1999-12-16 | 2003-05-20 | バイオストリーム セラピューティクス | １，３，４−置換ピペリジン類似体および嗜癖の治療におけるそれらの使用 |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| DE60324544D1 (de) | 2002-04-26 | 2008-12-18 | Schering Corp | Muskarin antagonisten |
| EP1802601A1 (en) | 2004-09-20 | 2007-07-04 | Targacept, Inc. | Azaspiroalkene and azapiroalkane compounds with nicotinic cholinergic receptor activity |
| GB0502509D0 (en) | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| US7977346B2 (en) | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
| US8202872B2 (en) | 2006-03-01 | 2012-06-19 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| TW200813051A (en) * | 2006-05-08 | 2008-03-16 | Neurogen Corp | Substituted azaspiro derivatives |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| US8809552B2 (en) | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| AR092289A1 (es) | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| ITMI20112329A1 (it) * | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| JP2017532364A (ja) * | 2014-10-31 | 2017-11-02 | インディビオール・ユー・ケイ・リミテッド | ドーパミンｄ３レセプターのアンタゴニスト化合物 |
-
2015
- 2015-10-30 JP JP2017523340A patent/JP2017532364A/ja active Pending
- 2015-10-30 WO PCT/GB2015/053272 patent/WO2016067043A1/en not_active Ceased
- 2015-10-30 EP EP15790229.7A patent/EP3212637B1/en active Active
- 2015-10-30 US US15/522,863 patent/US10000477B2/en active Active
- 2015-10-30 CA CA2964103A patent/CA2964103C/en active Active
- 2015-10-30 NZ NZ731118A patent/NZ731118A/en unknown
- 2015-10-30 SG SG11201702982UA patent/SG11201702982UA/en unknown
- 2015-10-30 MA MA040858A patent/MA40858A/fr unknown
- 2015-10-30 RU RU2017118562A patent/RU2017118562A/ru not_active Application Discontinuation
- 2015-10-30 AU AU2015340308A patent/AU2015340308B2/en active Active
- 2015-10-30 DK DK15790229.7T patent/DK3212637T3/da active
- 2015-10-30 KR KR1020177014318A patent/KR20170090422A/ko not_active Withdrawn
- 2015-10-30 MX MX2017005484A patent/MX2017005484A/es unknown
- 2015-10-30 ES ES15790229T patent/ES2883831T3/es active Active
- 2015-10-30 CN CN201580071094.4A patent/CN107108597B/zh active Active
-
2017
- 2017-04-13 IL IL251725A patent/IL251725B/en active IP Right Grant
- 2017-04-19 ZA ZA2017/02765A patent/ZA201702765B/en unknown
-
2018
- 2018-05-09 US US15/975,466 patent/US10239870B2/en active Active
-
2019
- 2019-01-29 US US16/261,206 patent/US10654842B2/en active Active
-
2020
- 2020-07-30 IL IL276400A patent/IL276400A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015340308B2 (en) | 2019-09-19 |
| US20180282318A1 (en) | 2018-10-04 |
| IL276400A (en) | 2020-09-30 |
| EP3212637B1 (en) | 2021-06-02 |
| DK3212637T3 (da) | 2021-07-12 |
| BR112017009042A2 (pt) | 2018-07-03 |
| ZA201702765B (en) | 2019-05-29 |
| RU2017118562A3 (enExample) | 2019-05-28 |
| CN107108597B (zh) | 2020-04-17 |
| US10239870B2 (en) | 2019-03-26 |
| RU2017118562A (ru) | 2018-11-30 |
| KR20170090422A (ko) | 2017-08-07 |
| ES2883831T3 (es) | 2021-12-09 |
| CA2964103C (en) | 2022-08-30 |
| EP3212637A1 (en) | 2017-09-06 |
| CN107108597A (zh) | 2017-08-29 |
| US10654842B2 (en) | 2020-05-19 |
| IL251725B (en) | 2020-08-31 |
| NZ731118A (en) | 2023-05-26 |
| CA2964103A1 (en) | 2016-05-06 |
| SG11201702982UA (en) | 2017-05-30 |
| US20170334895A1 (en) | 2017-11-23 |
| MX2017005484A (es) | 2017-10-20 |
| US10000477B2 (en) | 2018-06-19 |
| WO2016067043A1 (en) | 2016-05-06 |
| US20190300514A1 (en) | 2019-10-03 |
| IL251725A0 (en) | 2017-06-29 |
| JP2017532364A (ja) | 2017-11-02 |
| AU2015340308A1 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| MA40858A (fr) | Composés antagonistes des récepteurs d3 à la dopamine | |
| EP3558322A4 (en) | ANTIVIRAL BENZYL AMINE PHOSPHODIAMIDE COMPOUNDS | |
| EP3532069A4 (en) | ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS | |
| DK3440105T3 (da) | T-cellereceptorer | |
| DK3440106T3 (da) | T-cellereceptorer | |
| PL3494133T3 (pl) | Receptory limfocytów t anty-kras-g12d | |
| PT3223850T (pt) | Receptores de células t anti-kras mutado | |
| LT3197883T (lt) | Nauji junginiai | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| IL259947B (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| DK3143037T3 (da) | Alpha4beta7-integrin-thioether-peptidantagonister | |
| BR112016029361A2 (pt) | novos compostos substituídos por halogênio | |
| EP3464336A4 (en) | LINKS | |
| LT3713928T (lt) | Nauji bradikinino b2 receptoriaus antagonistai | |
| DK3104847T3 (da) | Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser | |
| EP3310352A4 (en) | CRYSTALLINE COMPOUNDS | |
| EP3529267C0 (en) | T CELL RECEPTOR | |
| PT3183242T (pt) | Compostos bicíclicos substituídos | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| DK3334721T3 (da) | Cgrp-receptorantagonister | |
| HUE039805T2 (hu) | Új szulfonilaminobenzamid vegyületek | |
| BR112017002509A2 (pt) | novos compostos substituídos com halogênio | |
| EP3865472C0 (en) | THROMBOXANE RECEPTOR ANTAGONISTS | |
| EP3325497A4 (en) | QUINSTATINVERBINDUNGEN |